People who inoculated Covid-19 vaccines by Pfizer and Moderna are up to 91 percent less likely to develop the disease, according to a US study which also suggests that the preventives reduce the severity of symptoms and duration in those who still get an infection.

The research, published in the New England Journal of Medicine on June 30, is among the first to show the benefits of mRNA vaccines even among those who experience breakthrough infections -- testing positive after immunization. "One of the unique things about this study is that it measured the secondary benefits of the vaccines," said study co-author Sarang Yoon, an assistant professor at the University of Utah, US.

 The study was designed to measure the risks and rates of infection among those on the front lines of the pandemic -- doctors, nurses, and first responders. The study found that mRNA Covid-19 vaccines were 91 percent effective in reducing risk for infection once participants were 'fully' vaccinated, two weeks after the second dose. The researchers also found that the vaccines are 81 percent effective in reducing risk for infection after "partial" immunisation, two weeks after the first dose was given.

The study recruited 3,975 participants at eight sites in the US. Participants submitted samples for Covid-19 testing on a weekly basis for 17 weeks between December 13, 2020 and April 10, 2021.

AIIMS Study: 41.7% of Kids slipped into depression, 22.5% developed significant fear of Covid

Covid-19 Third-wave likely to hit India in August: SBI Research

Study Synopsis on Malnutrition among under-five children in India